ToolGen툴젠

ToolGen remains deeply loss-making, with its share price down about half over the past year and a rights offering and filing amendments in progress.

ToolGen, a Korean gene-editing company, reported trailing twelve-month revenue of about ₩1.9B against an operating loss of about ₩23.8B for the half year to June 2026. Its share price closed at ₩27,900 on 23 October 2026, down 49.9% over one year and near its 52-week low of ₩27,350. Cash of about ₩8.6B and borrowings of about ₩0.2B are shown in the latest filed figures.

What stands out

• Trailing revenue of ₩1.9B is far below the operating loss of ₩23.8B, giving an operating margin of about -1,246%.
• Revenue has been volatile: it rose 46.6% in 2025 to ₩1.3B after falling 19.3% in 2024, and the company has posted losses in most years shown.
• Net income was positive only in 2024 (about ₩6.2B), which the data does not explain; 2025 and trailing net losses were about ₩36.8B and ₩34.7B.
• Recent filings include a rights offering with its issue price set in September 2026, plus several insider shareholding and a 5%+ holding report.
• Institutions were net sellers of about ₩2.6B over the last 20 days, while retail and foreign investors were net buyers; foreign ownership rose from 1.5% to 2.7% over 60 days.
• Valuation shows a price-to-book of 5.9 and price-to-sales of 142.6, with no meaningful earnings multiple because the company is loss-making.

What to watch

• Upcoming results and the outcome of the amended half-year report filed on 23 October 2026, which the data does not detail.
• Details and dilution effects of the rights offering and related securities issuance, which are not described in the data provided.
• Whether cash of about ₩8.6B is sufficient to fund the ongoing operating losses and negative free cash flow of about ₩23.9B.